Skip to search formSkip to main contentSkip to account menu

PDGFRA NP_006197.1:p.D842V

Known as: Platelet-Derived Growth Factor Receptor Alpha D842V, NP_006197.1:p.D842V, PDGFRA D842V 
A change in the amino acid residue at position 842 in the platelet-derived growth factor receptor alpha protein where aspartic acid has been replaced… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Creation and characterization of a novel human PDGFRA D842V-mutant GIST cell line.
e22512 Background: Activating PDGFRA mutations are seen in about 10% of gastrointestinal stromal tumors (GIST). Of these, the… 
2016
2016
Dose escalating study of crenolanib besylate in advanced GIST patients with PDGFRA D842V activating mutations.
11010Background: PDGFRA D842V mutated GIST is resistant to all available TKIs with a median PFS of ≤ 2.8m and a median OS 14.7m… 
2016
2016
Caractérisation des lignages myogéniques et adipocytaires chez l’animal en croissance : rôle du PDGFRa dans la balance myogenèse/adipogenèse
2014
2014
Correlation of PET/CT and CT RECIST response in GIST patients with PDGFRA D842V gene mutations treated with crenolanib.
10546 Background: Crenolanib (CP-868,596) is an orally bioavailable, selective inhibitor of platelet derived growth factor… 
2012
2012
p53-Mutation auch bei GIST relevant
Die Bedeutung von KIT- und PDGFRA-Mutationen bei gastrointestinalen Stromatumoren (GIST) ist bekannt (Abb.). Jetzt ging eine… 
2011
2011
The effect of crenolanib (CP-868596) on phosphorylation of the imatinib-resistant D842V PDGFRA activating mutation associated with advanced gastrointestinal stromal tumors.
10012 Background: 8-10% of gastrointestinal stromal tumors (GIST) have activating mutations of the platelet-derived growth factor… 
2011
2011
Abstract 3586: CP-868,596, a highly potent PDGFR inhibitor, inhibits phosphorylation of the imatinib-resistant PDGFRA D842V activating mutation associated with advanced GIST
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Background: 8-10% of gastrointestinal stromal tumors… 
2010
2010
Prognostic value of the most frequent mutations in GIST: Results of the French population-based prospective study MolecGIST.
10034 Background: More than 80% of gastrointestinal stromal tumors (GIST) have KIT or PDGFRA mutations, of which more than 100… 
2007
2007
Efficacité de l'imatinib dans les syndromes hyperéosinophiliques associés au transcrit FIP1L1-PDGFRA
2006
2006
Variable clinical response of hypereosinophilic syndromes (HES) to current therapeutic options.
16527 The term Hypereosinophilic syndrome (HES) refers to a heterogeneous group of disorders characterised by marked blood (>1500… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)